Title:Human Umbilical Cord Mesenchymal Stem Cells' Cultivation and Treatment
of Liver Diseases
Volume: 18
Issue: 3
Author(s): Zihe Zhu, Qianqian Zhang, Lixin Liu*Jun Xu*
Affiliation:
- Experimental Center of Science and Research, The First Clinical Hospital of Shanxi Medical
University, Taiyuan, Shanxi Province, China
- Hepatological surgery department, The First Clinical Hospital of Shanxi
Medical University, Taiyuan, Shanxi Province, China
Keywords:
Umbilical cord mesenchymal stem cells, 3D scaffold culture system, treatment, liver diseases, immunoregulation, mechanism.
Abstract:
Background: Over the past few years, mesenchymal stem cells (MSCs) have been regarded as
effective for treating various diseases. Among the types of MSCs, human umbilical cord mesenchymal
stem cells (hUC-MSCs) have been widely studied because of their advantages in non-invasive damage to
donors and the wide range of sources.
Main body: This article reviews three aspects of hUC-MSCs. Foremost are the latest advances in the
cultivation and preparation methods of hUC-MSCs. Furthermore, the treatments mechanism of hUCMSCs
in organ transplantation and liver diseases. Finally, a summary of their use in clinical trials in liver
diseases. The first part of this paper emphasizes the differences between the selection area and culture
factors, including the separation method, long-term culturing in vitro, medium composition, serum, and
three-dimensional (3D) skeleton system training, which could affect the characteristics of hUC-MSCs and
the treatment of diseases. The second section mainly stresses the mechanisms of hUC-MSCs in the treatment
of diseases, including immunoregulation and transdifferentiation into hepatocyte-like cells. Many
new technologies mark and track cells in vivo and their safety. Briefly mention its role in the treatment of
other diseases and vaccine preparation. In the third part, to accelerate the application of hUC-MSCs in the
treatment of clinical diseases, it is necessary to expand the sample size of clinical trials to ensure their
safety in the human body and determine the most effective infusion method and volume. Conclusion:
hUC-MSCs have a substantial potential to become a more effective treatment for liver diseases. Clinical
trials and mechanisms have laid the foundation for the normalization of clinical hUC-MSCs delivery.